Pharmacy TimesExperts Weigh In on GLP-1 Agonist Use in Pediatric Patients with Obesity

ASHP pharmacists clash over GLP-1 use in kids as young as 6, with prescriptions surging 500% since 2020 despite no long-term safety data on growth, puberty, or sustained weight outcomes. One in 4 US children now obese, creating pressure to prescribe drugs costing $500/month that patients likely need for life.

⚖️ PROFESSIONAL IMPACT

• Pediatric obesity guidelines from AAP now recommend weight intervention starting at age 2, creating ethical tension between early intervention and potential psychological harm from medicalizing weight in young children
• Insurance coverage collapsing as prescription rates explode—Medicare/Medicaid expected to drop coverage in 2026, leaving families with $500 monthly copays that don’t count toward deductibles
• Clinical trial data lacks standardized lifestyle intervention protocols, making it impossible to determine whether weight loss stems from medication, behavioral changes, or combination therapy in pediatric populations
• Immediate, significant weight rebound occurs when adolescents discontinue GLP-1s, raising questions about committing 6-year-olds to potentially lifelong pharmacotherapy without data on puberty, growth, or long-term metabolic effects

🎯 ACTION ITEMS

• Document family readiness to change, insurance coverage durability, and financial sustainability before initiating GLP-1 therapy in pediatric patients
• Counsel families that weight regain is immediate and significant upon discontinuation—this is lifelong therapy, not a temporary intervention
• Assess for depression and eating disorders at baseline and throughout treatment, as GI side effects may worsen psychological burden
• Advocate for standardized IHBLT protocols in your institution to establish true comparative effectiveness against pharmacotherapy

More in Obesity & Weight Management